Dln-101, DiaLean’s lead molecule, is being developed for the treatment of
Parkinson's disease. In addition, Dln-101 was approved for Phase 1 clinical trials for
the treatment of cachexia, a wasting disease manifested by unintentional weight loss
in many chronic diseases like cancer, COPD (Chronic Obstructive Pulmonary
Disease) and CHF (Congestive Heart Failure).